Hormonal contraception and metabolic outcomes in women with or at risk for HIV infection

Journal of Acquired Immune Deficiency Syndromes

Volumn 52, Issue 5, 2009, Pages 581-587

  Womack, Julie A ^a,b   Scherzer, Rebecca ^c   Cole, Stephen R ^d   Fennie, Kristopher ^a   Williams, Ann B ^a   Grey, Margaret ^a   Minkoff, Howard ^e   Anastos, Kathryn ^f   Cohen, Mardge H ^g   Tien, Phyllis C ^c,h  

^a YALE UNIVERSITY SCHOOL OF NURSING   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d IL   (United States)

^e STATE UNIVERSITY OF NEW YORK   (United States)

^f MONTEFIORE MEDICAL CENTER   (United States)

^g RUSH MEDICAL COLLEGE   (United States)

^h SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Depo Provera; HDL; HIV AIDS; Hormonal contraception; Triglycerides

Indexed keywords

ESTROGEN; GESTAGEN; GLUCOSE; HIGH DENSITY LIPOPROTEIN; INSULIN; LEVONORGESTREL; LIPID; LOW DENSITY LIPOPROTEIN; MEDROXYPROGESTERONE ACETATE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TRIACYLGLYCEROL; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ORAL CONTRACEPTIVE AGENT;

ADULT; ADVERSE OUTCOME; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIET RESTRICTION; DISORDERS OF CARBOHYDRATE METABOLISM; DISORDERS OF LIPID AND LIPOPROTEIN METABOLISM; ETHNIC DIFFERENCE; FEMALE; HOMEOSTASIS; HORMONAL CONTRACEPTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; INSULIN RESISTANCE; LIPID METABOLISM; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; ADOLESCENT; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; COHORT ANALYSIS; DRUG INTERACTION; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; RISK FACTOR; UNITED STATES;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; CHOLESTEROL, HDL; COHORT STUDIES; CONTRACEPTIVES, ORAL, HORMONAL; DRUG INTERACTIONS; ESTROGENS; FEMALE; GLUCOSE METABOLISM DISORDERS; HIV INFECTIONS; HUMANS; LIPID METABOLISM DISORDERS; MEDROXYPROGESTERONE ACETATE; MIDDLE AGED; PROGESTINS; RISK FACTORS; UNITED STATES;

EID: 73349098769     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181b9e5ee     Document Type: Article

References (36)

1. Kaiser Family Foundation. Women and HIV/AIDS in the United States. July 2007. The Henry J. Kaiser Family Foundation. Available at: www.kff.org. Accessed September 18, 2007.
2. CDC. HIV/AIDS Surveillance in Adolescents and Young Adults (Through 2005) [Slide Set]; 2007.
3. Hatcher R. Contraceptive Technology. 18th ed. New York: Ardent Media; 2004.
4. Grinspoon SK. Metabolic syndrome and cardiovascular disease in patients with human immunodeficiency virus. Am J Med. 2005;118(Suppl 2): S23-S28.
5. Godsland IF. The influence of female sex steroids on glucose metabolism and insulin action. J Intern Med Suppl. 1996;738:1-60.
6. Currier J, Scherzer R, Bacchetti P, et al. Regional adipose tissue and lipid and lipoprotein levels in HIV-infected women. J Acquir Immune Defic Syndr. 2008;48:35-43. (Pubitemid 351600850)
7. Womack J, Richman S, Tien PC, et al. Hormonal contraception and HIV-positive women: metabolic concerns and management strategies. J Midwifery Women Health. 2008;53:362-375.
8. Barkan SE, Melnick SL, Preston-Martin S, et al. The Women's Interagency HIV Study. WIHS Collaborative Study Group. Epidemiology. 1998;9:117-125.
9. Bacon MC, von Wyl V, Alden C, et al. The Women's Interagency HIV Study: an observational cohort brings clinical sciences to the bench. Clin Diagn Lab Immunol. 2005;12:1013-1019.
10. Klebanoff MA, Cole SR. Use of multiple imputation in the epidemiologic literature. Am J Epidemiol. 2008;168:355-357.
11. Rubin D. Inference and missing data. Biometrika. 1976;63:581-592.
12. Crawford SL, Tennstedt SL, McKinlay JB. A comparison of analytic methods for non-random missingness of outcome data. J Clin Epidemiol. 1995;48:209-219.
13. Rubin DB. Multiple imputation after 18+ years. J Am Stat Assoc. 1996;91: 473-489, 515-519.
14. Rubin DB. Multiple Imputation for Nonresponse in Surveys. New York: John Wiley & Sons Inc; 1987.
15. Allison P. Missing Data. Thousand Oaks, CA: Sage; 2001.
16. Riddler SA, Smit E, Cole SR, et al. Impact of HIV infection and HAART on serum lipids in men. JAMA. 2003;289:2978-2982.
17. Godsland IF, Crook D. Update on the metabolic effects of steroidal contraceptives and their relationship to cardiovascular disease risk. Am J Obstet Gynecol. 1994;170:1528-1536.
18. Crook D, Godsland IF, Worthington M, et al. A comparative metabolic study of two low-estrogen-dose oral contraceptives containing desogestrel or gestodene progestins. Am J Obstet Gynecol. 1993;169:1183-1189.
19. Kahn HS, Curtis KM, Marchbanks PA. Effects of injectable or implantable progestin-only contraceptives on insulin-glucose metabolism and diabetes risk. Diabetes Care. 2003;26:216-225.
20. Konje JC, Otolorin EO, Ladipo OA. Changes in carbohydrate metabolism during 30 months on Norplant. Contraception. 1991;44:163-172.
21. Konje JC, Odukoya OA, Otolorin EO, et al. Carbohydrate metabolism before and after Norplant removal. Contraception. 1992;46:61-69.
22. Shamma FN, Rossi G, HajHassan L, et al. The effect of Norplant on glucose metabolism under hyperglycemic hyperinsulinemic conditions. Fertil Steril. 1995;63:767-772.
23. Anastos K, Lu D, Shi Q, et al. Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens. J Acquir Immune Defic Syndr. 2007;45:34-42.
24. Knopp RH, LaRosa JC, Burkman RT Jr. Contraception and dyslipidemia. Am J Obstet Gynecol. 1993;168:1994-2005.
25. Garza-Flores J, De la Cruz DL, Valles de Bourges V, et al. Long-term effects of depot-medroxyprogesterone acetate on lipoprotein metabolism. Contraception. 1991;44:61-71.
26. Amatayakul K, Sivassomboon B, Singkamani R. Effects of medrox-yprogesterone acetate on serum lipids, protein, glucose tolerance and liver function in Thai women. Contraception. 1980;21:283-297.
27. Gershberg H, Zorrilla E, Hernandez A, et al. Effects of medroxyproges-terone acetate on serum insulin and growth hormone levels in diabetics and potential diabetics. Obstet Gynecol. 1969;33:383-389.
28. Vermeulen A, Thiery M. Hormonal contraceptives and carbohydrate tolerance. II. Influence of medroxyprogesterone acetate and chronic oral contraceptives. Diabetologia. 1974;10:253-259.
29. Godsland IF, Crook D, Wynn V. Coronary heart disease risk markers in users of low-dose oral contraceptives. J Reprod Med. 1991;36(3 Suppl):226-237.
30. Wynn V, Godsland I. Effects of oral contraceptives on carbohydrate metabolism. J Reprod Med. 1986;31(9 Suppl):892-897.
31. Wynn V, Adams PW, Godsland I, et al. Comparison of effects of different combined oral-contraceptive formulations on carbohydrate and lipid metabolism. Lancet. 1979;313:1045-1049.
32. Kim C, Seidel KW, Begier EA, et al. Diabetes and depot medroxypro-gesterone contraception in Navajo women. Arch Intern Med. 2001;161: 1766-1771.
33. Kjos SL, Peters RK, Xiang A, et al. Contraception and the risk of type 2 diabetes mellitus in Latina women with prior gestational diabetes mellitus. JAMA. 1998;280:533-538.
34. Clark RA, Theall KP. Trends and correlates of hormonal contraception use among HIV-infected women. J Acquir Immune Defic Syndr. 2004;36: 986-988.
35. Greenland S, Finkle WD. A critical look at methods for handling missing covariates in epidemiologic regression analyses. Am J Epidemiol. 1995; 142:1255-1264.
36. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Department of Health and Human Services; 2008. Available at: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed October 1, 2008.